hepatocellular carcinama
Conditions
Interventions
Case series:Immunomonotherapy or combined TACE or targeted therapy
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with primary liver cancer diagnosed by histopathology or cytology combined with at least one of the above high-risk relapse factors; 2. Postoperative patients who receive immunotherapy single drug or immunotherapy combined with TACE or immunotherapy combined targeted therapy; 3. ECOG function score 0-1; 4. Aged 18-70 years old; 5. Be fully informed about treatment methods, sign informed consent, and actively cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Postoperative pathological non-hepatocellular carcinoma patients; 2. Participating in other clinical trials; 3. Merged with other malignant tumors; 4. Uncontrollable systemic hemorrhagic diseases, severe blood hypercoagulability, severe coagulopathy, or subjects are using drugs that affect blood coagulation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| circulating tumor cell;Relapse rate, metastasis rate;overall survival rate;recurrence -free survival rate; | — |
Countries
china
Contacts
Public ContactQiu Jianguo
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed